
    
      This is a Phase 1, open-label study of DS-3078a to assess safety and tolerability, identify
      the maximum tolerated dose (MTD) and tentative recommended phase 2 dose (RP2D), and assess
      pharmacokinetic and pharmacodynamic properties in subjects with advanced solid tumor
      malignancies or lymphomas. The study will include 2 parts: Dose Escalation and Dose
      Expansion.
    
  